Private Portfolio Partners LLC Acquires 2,790 Shares of Johnson & Johnson (NYSE:JNJ)

Private Portfolio Partners LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 26.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,222 shares of the company’s stock after acquiring an additional 2,790 shares during the period. Private Portfolio Partners LLC’s holdings in Johnson & Johnson were worth $1,842,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in JNJ. Zions Bancorporation N.A. increased its position in shares of Johnson & Johnson by 0.4% during the second quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after acquiring an additional 73 shares during the period. Cambridge Advisors Inc. increased its position in shares of Johnson & Johnson by 0.3% during the fourth quarter. Cambridge Advisors Inc. now owns 22,436 shares of the company’s stock worth $2,895,000 after acquiring an additional 78 shares during the period. Vishria Bird Financial Group LLC increased its position in shares of Johnson & Johnson by 3.0% during the second quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after acquiring an additional 80 shares during the period. Burt Wealth Advisors increased its position in shares of Johnson & Johnson by 0.6% during the fourth quarter. Burt Wealth Advisors now owns 12,898 shares of the company’s stock worth $1,665,000 after acquiring an additional 82 shares during the period. Finally, Timber Creek Capital Management LLC increased its position in shares of Johnson & Johnson by 8.7% during the fourth quarter. Timber Creek Capital Management LLC now owns 1,035 shares of the company’s stock worth $133,000 after acquiring an additional 83 shares during the period. 72.01% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently commented on JNJ shares. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Barclays started coverage on shares of Johnson & Johnson in a research report on Friday, June 21st. They set a “hold” rating and a $140.00 target price on the stock. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Morgan Stanley reaffirmed an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Buy” and an average target price of $150.60.

JNJ stock traded down $0.01 during trading on Thursday, hitting $130.40. 2,681,736 shares of the company’s stock traded hands, compared to its average volume of 7,507,391. The firm has a market capitalization of $341.88 billion, a P/E ratio of 15.94, a PEG ratio of 2.19 and a beta of 0.68. The business has a fifty day simple moving average of $130.05 and a two-hundred day simple moving average of $135.78. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1 year low of $121.00 and a 1 year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. Johnson & Johnson’s revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company posted $2.10 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.91%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s payout ratio is 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Do You Need a Fiduciary?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.